AbbVie Sees Solid Japan Outlook Despite 2020 Dip
Multi-Indication Pipeline
Executive Summary
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.
You may also be interested in...
Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan
A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.
Research Industry Presents United Front On Japan Reforms
Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system.
Viatris And FKB Introduce First Japanese Adalimumab Biosimilar
Viatris and Fujifilm Kyowa Kirin Biologics have introduced Japan’s first biosimilar rival to Humira.